The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

Dalian Seventh People's Hospital

Status: Unknown

Conditions: Micrognathia; Schizophrenia

Treatments: Other: atypical antipsychotic combined with MECT; Drug: Atypical Antipsychotic

Study type: Observational

Funder types: Other

Identifiers

NCT03007303

GFu01

Details and patient eligibility

About

This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.

Full description

The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR).

The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least.

This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.

Enrollment: 30 estimated patients

Sex: All

Ages: 17 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Persons should be diagnosed with schizophrenia according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)
• The first-onset or drug-free in the latest 3 months
• Between the ages of 17-40

Exclusion criteria

• Comorbid with other psychosis
• Have physical or neurological diseases such as traumatic brain injuries
• History of drug-abused or alcoholic
• Blood transfusion history in a month
• Been treated with Modified Electric Convulsive Therapy(MECT) in late 3 months

Trial design

30 participants in 2 patient groups

schizophrenia

Description:

15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT. The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated.

Treatment:

Drug: Atypical Antipsychotic

Other: atypical antipsychotic combined with MECT

health controls

Description:

15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group